Irregular Periods: Drugs That Cause or Treat It

What Counts as an Irregular Period?

A normal menstrual cycle runs 21 to 35 days from the first day of one period to the first day of the next, with bleeding lasting 2 to 7 days and total blood loss under 80 mL per cycle. Anything outside those boundaries, including cycles that vary by more than 7 to 9 days from month to month, meets the clinical definition of menstrual irregularity. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 136 defines abnormal uterine bleeding associated with ovulatory dysfunction as one of the eight PALM-COEIN categories of abnormal uterine bleeding.

Oligomenorrhea vs. Amenorrhea vs. Polymenorrhea

Oligomenorrhea means cycles longer than 35 days. Amenorrhea is the absence of menstruation for 90 or more days (primary amenorrhea is no period by age 15; secondary amenorrhea is cessation after established cycles). Polymenorrhea describes cycles shorter than 21 days. Each pattern carries a different differential diagnosis and changes which tests your clinician orders first.

Why the Distinction Matters Clinically

Chronic anovulation from any cause raises lifetime endometrial cancer risk because unopposed estrogen stimulates the uterine lining without the protective effect of progesterone. A 2020 systematic review in the Journal of the National Cancer Institute found that women with irregular cycles had a statistically significantly higher risk of endometrial cancer compared with women with regular cycles (RR 1.45, 95% CI 1.18 to 1.77).

Common Non-Drug Causes of Irregular Periods

Before attributing cycle disruption to a medication, clinicians rule out underlying conditions because those conditions often require their own treatment.

Polycystic Ovary Syndrome

PCOS is the single most common cause of chronic anovulation in reproductive-age women, affecting 6 to 13% of the global female population according to a 2023 Endocrine Society Clinical Practice Guideline. The guideline defines PCOS by the Rotterdam criteria: two of three findings (oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound). Women with PCOS frequently have cycles lasting 35 to 90 days or achieve fewer than eight periods per year.

Thyroid Dysfunction

Both hypothyroidism and hyperthyroidism disrupt the hypothalamic-pituitary-ovarian axis. A 2015 study published in the European Journal of Endocrinology found that subclinical hypothyroidism (TSH 4.5 to 10 mIU/L) was associated with anovulatory cycles in 23.4% of affected women. Treating the thyroid disorder alone restores regular cycles in most cases within 3 to 6 months.

Hyperprolactinemia

Elevated serum prolactin suppresses GnRH pulsatility, reducing LH and FSH secretion and producing oligomenorrhea or amenorrhea. The most common causes are a pituitary prolactinoma, stress, and, critically, several drug classes discussed in the next section. An NIH review of pituitary disorders notes that prolactin levels above 100 ng/mL almost always indicate a macroprolactinoma rather than a drug effect.

Hypothalamic Amenorrhea

Caloric restriction below roughly 30 kcal/kg of fat-free mass per day, excessive aerobic exercise, or significant psychological stress can suppress GnRH pulsatility enough to halt ovulation entirely. Athletes and women with restrictive eating patterns are disproportionately affected. A 2021 position statement from the Female Athlete Triad Coalition recommends energy intake restoration as the primary intervention, not pharmacotherapy.

Perimenopause

Cycle variability is the first menstrual change of perimenopause, typically appearing in the mid-to-late 40s. FSH begins rising while cycle length becomes erratic, with some cycles shortening to 21 to 24 days and others extending beyond 60 days. ACOG Committee Opinion No. 773 notes that perimenopause can last 4 to 8 years before the final menstrual period.

Drugs That Cause Irregular Periods

Many medications alter menstrual regularity through hormonal, neurochemical, or metabolic mechanisms. The categories below represent the most clinically significant offenders.

Hormonal Contraceptives

Progestin-only pills (the "mini-pill"), progestin implants (etonogestrel implant, Nexplanon), and progestin-only injectables (medroxyprogesterone acetate 150 mg IM, Depo-Provera) are the most frequent pharmaceutical causes of irregular bleeding. The etonogestrel implant produces unpredictable bleeding in approximately 22% of users at 1 year, according to FDA prescribing information for Nexplanon. Depo-Provera causes amenorrhea in about 50% of users after 12 months of use and can delay return of ovulation for 6 to 18 months after the last injection.

Combined oral contraceptives (COCs) typically regulate bleeding, but missed pills, starting a new formulation, or using a continuous-dosing regimen without a hormone-free interval can all produce breakthrough bleeding or oligomenorrhea.

Antipsychotics and Dopamine Antagonists

First-generation antipsychotics (haloperidol, chlorpromazine) and several second-generation agents (risperidone, paliperidone) block dopamine D2 receptors in the tuberoinfundibular pathway, raising prolactin levels significantly. Risperidone raises prolactin to a mean of 45 to 100 ng/mL in women, compared with a normal range of 2 to 29 ng/mL, according to a 2021 meta-analysis in Schizophrenia Bulletin. Olanzapine and quetiapine produce comparatively less prolactin elevation because of faster D2 dissociation.

Metoclopramide and domperidone, used for nausea and gastroparesis, share this dopamine-blocking mechanism and can cause oligomenorrhea or amenorrhea with chronic use.

Chemotherapy and Gonadotoxic Agents

Alkylating agents (cyclophosphamide, busulfan, chlorambucil) are the most gonadotoxic chemotherapeutic drugs. They damage primordial follicles directly, producing premature ovarian insufficiency (POI) at rates that scale with cumulative dose and patient age. A 2011 study in Fertility and Sterility found that women under age 30 receiving cyclophosphamide for autoimmune disease had a 12 to 27% rate of POI within 2 years, rising to 50 to 70% in women over 40. GnRH agonist co-therapy during chemotherapy may reduce this risk, though evidence remains debated.

GnRH Agonists and Antagonists

Leuprolide (Lupron), used for endometriosis, uterine fibroids, and certain cancers, produces a medical menopause by downregulating GnRH receptors after an initial flare. Amenorrhea typically begins 4 to 8 weeks into therapy and reverses within 3 to 6 months of stopping in most patients. GnRH antagonists (elagolix, Orilissa) produce a dose-dependent suppression of estrogen and amenorrhea in 17 to 52% of users depending on dose, as shown in the ENDO I trial (N=872) published in the New England Journal of Medicine.

Thyroid Medications

Excess levothyroxine (over-replacement causing suppressed TSH) can accelerate cycles, producing polymenorrhea or shorter-than-normal cycle lengths. Conversely, undertreated hypothyroidism perpetuates the irregular cycles caused by the disease itself. Methimazole and propylthiouracil, used for hyperthyroidism, can indirectly regularize cycles once euthyroidism is restored, but antithyroid drugs themselves carry a small risk of agranulocytosis and are adjusted by serum FT4 rather than cycle pattern. FDA prescribing data for methimazole lists menstrual irregularity as an adverse effect of the drug class.

Anticoagulants and NSAIDs

Warfarin and direct oral anticoagulants (DOACs, including rivaroxaban and apixaban) do not directly disrupt ovulation but can produce heavier, longer periods (heavy menstrual bleeding, HMB) that make cycles appear irregular. NSAIDs taken chronically can delay ovulation through prostaglandin inhibition; a 2015 study in Human Reproduction found that diclofenac 100 mg/day for 10 days around ovulation produced a luteinized unruptured follicle (LUF) phenomenon in 75% of cycles studied, effectively preventing ovulation.

Antiepileptic Drugs

Valproate increases androgen levels and may produce PCOS-like ovarian morphology in women with epilepsy. A 2004 study in Epilepsia found that 43% of women starting valproate for epilepsy developed polycystic ovaries or hyperandrogenism within 12 months. Enzyme-inducing antiepileptics (carbamazepine, phenytoin, oxcarbazepine) accelerate estrogen metabolism via CYP3A4 induction, reducing the efficacy of hormonal contraceptives and altering cycle dynamics.

Other Notable Agents

• Corticosteroids (prednisone, dexamethasone): Suppress the HPO axis with doses above the equivalent of approximately 7.5 mg/day prednisone for more than 4 weeks. A CDC analysis noted corticosteroid use as a recognized contributing factor to secondary amenorrhea in women of reproductive age.
• Opioids: Chronic opioid use suppresses LH pulsatility. A 2015 review in the Journal of Pain Research found that 40 to 85% of women on long-term opioid therapy develop opioid-induced androgen deficiency and menstrual disturbance.
• Spironolactone: At doses above 100 mg/day, spironolactone commonly causes irregular bleeding by blocking progesterone receptors. Adding a low-dose OCP (e.g., drospirenone/ethinyl estradiol) typically resolves this.
• SSRIs and SNRIs: Mild prolactin elevation occurs with most SSRIs, though clinically significant menstrual disruption is rare. A 2013 pharmacovigilance analysis in Drug Safety found menstrual irregularity reported in fewer than 3% of women on SSRI monotherapy.

Diagnosing the Cause of Irregular Periods

Getting the diagnosis right determines treatment. Clinicians typically follow a stepwise approach.

Initial Laboratory Panel

The first-line workup for irregular periods in a reproductive-age woman includes:

1. Urine or serum hCG to exclude pregnancy
2. Serum TSH to screen for thyroid dysfunction
3. Serum prolactin to detect hyperprolactinemia
4. Serum FSH and LH to distinguish ovarian insufficiency (high FSH) from hypothalamic amenorrhea (low or normal FSH/LH)
5. Free and total testosterone, DHEA-S if PCOS or androgen excess is suspected

ACOG Practice Bulletin No. 194 recommends serum AMH as an adjunct in PCOS evaluation but not as a standalone diagnostic criterion.

Pelvic Ultrasound

Transvaginal ultrasound is the preferred imaging modality for assessing ovarian morphology (12 or more follicles 2 to 9 mm per ovary meets the Rotterdam polycystic ovarian morphology criterion) and endometrial thickness. Women with oligomenorrhea or amenorrhea lasting more than 90 days may accumulate endometrial lining and require assessment for hyperplasia.

Endometrial Biopsy Indications

Any woman over age 45 with irregular bleeding, or a younger woman with risk factors (obesity, chronic anovulation, diabetes, tamoxifen use) and irregular bleeding lasting more than 6 months, should have an endometrial biopsy to exclude hyperplasia or carcinoma. This recommendation aligns with the 2012 ACOG Practice Bulletin No. 128 on endometrial cancer.

Drugs Used to Treat Irregular Periods

Treatment targets the underlying mechanism. The options below are organized by indication.

Restoring Cycle Regularity in PCOS

Combined oral contraceptives are first-line for managing cycle irregularity in PCOS when fertility is not desired. A 2023 Endocrine Society guideline states: "Combined oral contraceptives are recommended for the management of menstrual irregularity and hyperandrogenism in women with PCOS who do not wish to conceive." The same guideline specifies that any COC formulation containing 20 to 35 mcg ethinyl estradiol is acceptable, with no evidence that one progestin type is clearly superior for cycle control.

Metformin is an insulin sensitizer approved for type 2 diabetes but used off-label in PCOS to improve ovulatory frequency. In the PPCOS II trial (N=750) published in the New England Journal of Medicine, metformin alone (1,000 mg twice daily) achieved a live-birth rate of 7.2% over 6 months compared with 5.8% for placebo, but clomiphene performed significantly better than both. Metformin does reduce the proportion of anovulatory cycles and is often added to COC therapy in women with insulin resistance.

Cyclic progesterone provides endometrial protection in women who are anovulatory but not candidates for COCs. Medroxyprogesterone acetate 10 mg daily for 10 to 14 days every 1 to 3 months induces a withdrawal bleed and prevents endometrial hyperplasia. Oral micronized progesterone (Prometrium 200 mg nightly for 12 days) is an alternative with a more favorable side-effect profile.

Ovulation Induction When Pregnancy Is Desired

Letrozole (2.5 to 7.5 mg on cycle days 3 to 7) is now the preferred first-line ovulation induction agent in PCOS-related anovulatory infertility. In the landmark PPCOS II trial, letrozole produced a live-birth rate of 27.5% over 6 months compared with 19.1% for clomiphene (P<0.001), with lower rates of multiple gestation.

Clomiphene citrate (50 to 150 mg on cycle days 3 to 7) remains widely used and FDA-approved for ovulation induction, achieving ovulation in 70 to 85% of PCOS patients and pregnancy in approximately 30 to 40% over 6 cycles, per data from the SART registry.

Gonadotropins (recombinant FSH, urofollitropin) are reserved for clomiphene/letrozole-resistant anovulation or for IUI/IVF cycles. They require close ultrasound monitoring to minimize ovarian hyperstimulation syndrome (OHSS) risk.

Treating Drug-Induced Hyperprolactinemia

If an antipsychotic is the confirmed cause of elevated prolactin and cycle disruption, the preferred strategy depends on psychiatric stability. Switching to a prolactin-sparing antipsychotic (aripiprazole, quetiapine) resolves hyperprolactinemia in most cases within 4 to 8 weeks. Adding low-dose aripiprazole (5 to 15 mg/day) to risperidone is an alternative strategy supported by a 2015 RCT in Psychoneuroendocrinology (N=60), which showed normalization of prolactin in 80% of patients.

Dopamine agonists (cabergoline 0.25 to 1.0 mg twice weekly, bromocriptine 1.25 to 2.5 mg twice daily) are first-line for prolactinoma-driven hyperprolactinemia. A Cochrane review (2012) found cabergoline superior to bromocriptine in normalizing prolactin (83% vs. 59%) and restoring regular menses (75% vs. 45%).

Treating Hypothalamic Amenorrhea

The primary treatment for hypothalamic amenorrhea is non-pharmacological: restoring energy availability, reducing exercise load, and addressing psychological stressors. When bone loss is a concurrent concern, transdermal estradiol (0.05 to 0.1 mg/day patch) with cyclic oral progesterone is preferred over COCs for bone protection, based on a 2017 RCT in the New England Journal of Medicine (N=87) showing that transdermal estradiol with oral progesterone significantly increased lumbar spine BMD (P<0.0001) compared with placebo at 18 months.

Recombinant leptin and kisspeptin are investigational agents being studied for hypothalamic amenorrhea but are not yet FDA-approved for this indication.

Treating Thyroid-Related Cycle Disruption

Levothyroxine dose titration to maintain TSH in the 0.5 to 2.5 mIU/L range restores regular cycles in most women with hypothyroidism within 3 to 6 months. No additional hormonal therapy is needed if thyroid function is adequately controlled. An NIH resource on thyroid disease confirms that menstrual regularization is an expected outcome of euthyroidism restoration.

Treating Endometriosis-Related Cycle Abnormalities

GnRH antagonists, specifically elagolix (Orilissa 150 mg once daily or 200 mg twice daily), are FDA-approved for moderate-to-severe endometriosis-associated pain. The 200 mg twice-daily dose produces amenorrhea in approximately 52% of patients, useful for managing painful, heavy cycles, but carries a dose-dependent estrogen-deficiency risk for bone density. FDA prescribing information for Orilissa limits continuous use of the higher dose to 6 months.

Norethindrone acetate 5 mg/day and dienogest 2 mg/day (not available in the U.S.) are progestin-only options that suppress endometrial tissue and typically produce amenorrhea or very light, infrequent bleeding, reducing cycle-related symptoms.

When to Seek Medical Attention

Cycle irregularity that persists for three or more consecutive months outside the 21 to 35-day window warrants evaluation, even in the absence of other symptoms. Immediate evaluation is appropriate for:

• Bleeding so heavy it requires changing a pad or tampon more than once per hour for two consecutive hours
• Complete absence of periods for 90 or more days in a woman who is not pregnant, breastfeeding, or postmenopausal
• Cycle disruption after starting a new prescription medication (document timing and report to the prescribing clinician)
• Irregular periods accompanied by significant hair loss, galactorrhea, vision changes, or severe pelvic pain

The American Society for Reproductive Medicine (ASRM) Practice Committee Opinion on Optimal Evaluation of the Infertile Female recommends expedited evaluation (within 3 to 6 months rather than the standard 12) for any woman with known or suspected ovulatory dysfunction, regardless of age.